NEW YORK (GenomeWeb News) – PerkinElmer this week said that its board of directors has declared a quarterly dividend of $.07 per share of common stock. The dividend is payable on Aug. 12, to all shareholders of record as of the close of business on July 22.
The firm also said this week that is has acquired Dexela, a London-based provider of flat panel Complementary Metal-Oxide-Semiconductor X-ray detection technologies and services. The deal expands PerkinElmer's medical imaging portfolio in surgery, dental CT, cardiology, and mammography, as well as non-destructive testing. The purchase price was not disclosed.
Pathwork Diagnostics announced that palmetto GBA, the Medicare contractor for California, has issued a positive coverage policy for the firm's Pathwork Tissue of Origin Test, which identifies the primary tumor in difficult to diagnose cancer cases. The test will be covered for Medicare patients across the nation, said Pathwork.
BioNanomatrix has moved its headquarters to San Diego from Philadelphia. The firm's new headquarters are located along the Torrey Pines Mesa life science corridor. It has disclosed plans to expand on the West Coast a few months ago, when it closed on a $23.3 million Series B financing round.
Galaxy Diagnostics, a startup developing PCR-based tests for hard-to-detect bacteria, has opened a new clinical testing lab at the Alexandria Innovation Center in Research Triangle Park, NC. The firm recently graduated from the First Flight Venture Center and is currently seeking Clinical Laboratory Improvement Act approval for its lab to run tests on human blood samples.
Malaysian Genomics Resource Centre Berhad said this week that it has completed the sequencing and assembly of the Ganoderma boninense fungus genome. Research on the fungus, which causes basal stem rot in oil palm, was conducted by MGRC and Felda Agricultural Services. The sequence data is available on MGRC's website.
The Structural Genomic Consortium said this week that it will work with Cerep in developing open-access biochemical and cell-based assays for the discovery of small molecule chemical probes and drug candidates for epigenetic targets. As part of the collaboration, Cerep intends to open a lab in Toronto that will offer screening and profiling services.